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The targeted and conditional activation of pharmaceuticals is an increasingly important feature in modern 
personalized medicine. Nucleic acid nanoparticles show tremendous potential in this exploit due to their 
programmability and biocompatibility. Among the most powerful nucleic acid specific treatments is RNA 
interference-based therapeutics. RNA interference is a naturally occurring phenomenon in which specific genes 
are effectively silenced. Recently we have developed two different strategies based on customized multivalent 
nucleic acid nanoparticles with the ability to conditionally activate RNA interference in diseased cells as well as 
elicit detectable fluorescent responses.[1,2] These novel technologies can be further utilized for the simultaneous 
delivery and conditional intracellular activation of multiple therapeutic and biosensing functions to combat 
various diseases. 
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Nucleic acid nanoparticles have become increasingly 
attractive in therapeutic research due to their high 
customizability and various functionalities while retaining 
biocompatibility and ease in production [3-10]. Specifically, 
RNA has garnered attention through research exploiting its 
plethora of functionalities in sensing and treating various 
diseases. RNA interference (RNAi) which is the effective 
termination of specific protein production, serves as an 
important aspect of RNA therapeutics [11-13]. RNAi occurs 
naturally through various pathways but can be taken 
advantage of synthetically using a number of designed RNA 
strands (i.e., short-interfering RNA, or siRNA, and slightly 
elongated dicer-substrate RNA or DS RNA [14]). The ability 
to simultaneously deliver and activate multiple 
functionalities (including but not limited to RNAi) would 
prove immensely beneficial to personalized medicine. 
Additionally, predicting the structure, folding, and tertiary 
interactions of RNA would greatly benefit and accelerate the 
design of therapeutics. 
We introduced nucleic acid-based programmable system 
with the ability to conditionally activate multiple 
functionalities via introduction of split cognate strands [15-16]. 
Each strand contributes half of a designed DS RNA duplex, 
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which upon re-association and further dicing forms a 
functional therapeutic. The initially prepared non-functional 
DNA-RNA hybrids contain either ssDNA or, as in the 
highlighted work [2], ssRNA over-hangs of different lengths, 
called toeholds (Figure 1A). These toeholds allow for the 
non-functional cognate hybrids to interact and, through 
branch migration, form more energetically suitable 
complexes – that is the formation of DS RNA. To allow for 
multiple functionalities to be delivered and activated 
simultaneously, previously designed RNA rings [17] were 
used in this work as scaffolds carrying six hybrids. The 
efficacy of re-association based on varying toehold length 
was assessed using both native-PAGE and FRET. Toeholds 
of 2, 4, 6, and 8 nucleotides were investigated for their 
efficiency of re-association. FRET analyses revealed that 
longer toeholds led to improved re-association rates. The 
functionality of these particles was confirmed in different 
human cell lines. 
The previously mentioned functionality operates using 
DNA-RNA hybrids. An additional scheme has also been 
exploited using RNA-RNA interactions (Figure 1B).[1] In this 
system an RNA strand is designed to interact with specific 
mRNA strands in cells. The designed RNA strand contains 
both “therapeutic” and “trigger” components; these two 
components are designed to dissociate from each other in the 
presence of a “trigger” mRNA and form both a byproduct as 
well as a short hairpin-like RNA which can be processed by 
dicer to form functional siRNA. The conformational change 
takes place due to the presence of an extended ssRNA 
toehold in the “trigger”-binding strand which allows for the 
specific binding to an mRNA present in diseased cells. This 
novel approach allows for the conditional activation of 
therapeutic RNAs only where a designated trigger strand is 
present. For potential use in treatment of diseases, such as 
cancer, this can be a tremendous boon as it will reduce off 
target silencing and allow for more precise treatment. 
Rational design of these RNA nanoparticles was performed 
using HyperFold, a novel multistrand nucleic acid modeling 
approach used for predicting structures and interactions 
between nucleic acid strands as well as the formation of 
pseudoknots (RNA structures with non-nested base pairing). 
This in silico approach supplemented in vitro experiments to 
confirm RNA structures and interactions. 
The conditionally activated RNA nanoparticles, published 
back-to-back in Nano Letters [1, 2], offer alternative 
techniques supplementing each other. The combination of 
these technologies provides the ability to deliver multiple 
functionalities simultaneously. Currently there are two 
Figure 1. Schematic representation of two alternative ways, described in highlighted papers, to conditionally 
activate various functionalities intracellularly. A: corresponds to the hybrid approach and B: corresponds to the two 
stranded switch approach. 
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synthesis techniques for constructing these architectures and 
their functional moieties: transcription of individual 
components followed by a one pot assembly, as is the case 
for the switch, or co-transcriptional assembly, as in the case 
of the hybrid nanostructures. The former consists of 
transcribing DNA strands separately, then purifying and 
recombining in equimolar concentration by heating (causing 
denaturation) and snap-cooling to achieve the designed 
conformation. The latter is a more simplistic approach as it 
can be done in one step and offers great promise for an 
alternative pathway to functionalization of particles in vivo. 
There are other approaches of designed RNA constructs 
that can switch between different conformations. For 
example, riboregulators have been developed, that enable 
protein translation conditional to the binding of a trigger 
RNA [18]. In a bacterial system, designed riboswitches that 
are responsive to temperature and binding of a ligand were 
recently shown to be able to regulate both transcriptional and 
translational efficiency [19]. Such approaches are not 
necessarily in competition, but instead have different uses. 
The two aforementioned approaches are well suited for 
designing reporter genes or gene circuits but require the de 
novo design of genomic regions upstream of the translation 
start site of a gene. The conditional activation of RNA 
interference (the focus of this research highlight) on the other 
hand, is based on comparatively short synthetic noncoding 
RNAs that function in the context of human cancer cells and 
are thus closer to traditional small molecule therapeutics. Not 
only will it be interesting to compare these different novel 
tools for the “smart” control of gene expression: exciting 
opportunities abound to combine such approaches, leading to 
systems that allow ever more complex control of the cellular 
machinery by operating on different levels simultaneously. 
Overall, published techniques can be used in conjunction 
with pre-existing nucleic acid nanostructures thus increasing 
the control over the formulation and co-delivery of 
pharmaceuticals and biosensors for the treatment and 
detection of a large variety of diseases. 
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